Correction to: BMC Urol (2020) 20:40
https://doi.org/10.1186/s12894-020-00609-2
It was highlighted that the original article [1] contained the below errors in Tables 2, 3 and 4 and in the legends of Tables 3 and 4. This Correction article shows the correct Tables and legends.
In Table 2, for Stage I – SCSTs the number for “uninsured” and “privately insured” was swapped. The distribution should be uninsured = 20 (8%); privately insured = 169 (65%)
In Table 3, multivariable HR for Uninsured should read HR 2.31, 95% CI 2.01–2.66. Additionally, Urban/Rural should read HR 1.13, 95% CI 1.00–1.29. Among those with Stage II/III tumors, for percent of individuals in the patient’s ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52–0.88. In Table 4, for stage II/III, HR for income >$63 k should read HR 0.79, 95% CI 0.61–1.02. Additionally, for stage II/III, for percent of individuals in the patient’s ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52–0.88.
In Table 4, for stage II/III, HR for income >$63 k should read HR 0.79, 95% CI 0.61–1.02. Additionally, for stage II/III, for percent of individuals in the patient’s ZIP code without a high school diploma, the less than 7% group should read HR 0.67, 95% CI 0.52–0.88.
Table legend corrections: For Table 3, the definition of the abbreviation “IQR” is unnecessary. Table 4 was missing the following - CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors, *p < 0.05, **p < 0.01, ***p < 0.001
Table 2.
Stage-specific comparison of the sociodemographic and clinical characteristics of patients with SCSTs versus GCTs
| Factor | Stage I | Stage II/III | ||||
|---|---|---|---|---|---|---|
| SCSTs | GCTs | p-value | SCSTs | GCTs | p-value | |
| N | 259 | 32,204 | 21 | 9708 | ||
| Age at diagnosis, median (IQR) | 43 (34, 57) | 34 (28, 43) | < 0.001 | 55 (42, 64) | 33 (26, 42) | < 0.001 |
| Diagnosis year | < 0.001 | 0.38 | ||||
| 2004–2005 | 46 (18%) | 6387 (20%) | 2 (10%) | 1780 (18%) | ||
| 2006–2007 | 33 (13%) | 6416 (20%) | 6 (29%) | 1874 (19%) | ||
| 2008–2009 | 45 (17%) | 6528 (20%) | 5 (24%) | 1942 (20%) | ||
| 2010–2011 | 75 (29%) | 6487 (20%) | 6 (29%) | 1993 (21%) | ||
| 2012–2013 | 60 (23%) | 6386 (20%) | 2 (10%) | 2119 (22%) | ||
| Race/ethnicity | < 0.001 | 0.62 | ||||
| Non-Hispanic White | 157 (61%) | 25,125 (78%) | 17 (81%) | 7266 (75%) | ||
| Non-Hispanic Black | 47 (18%) | 809 (3%) | 1 (5%) | 311 (3%) | ||
| Hispanic/Other | 52 (20%) | 5672 (18%) | 3 (14%) | 2000 (21%) | ||
| Unknown | 3 (1%) | 598 (2%) | 0 (0%) | 131 (1%) | ||
| Insurance | < 0.001 | 0.087 | ||||
| Uninsured | 20 (8%) | 3411 (11%) | 4 (19%) | 1351 (14%) | ||
| Private insurance | 169 (65%) | 24,575 (76%) | 9 (43%) | 6339 (65%) | ||
| Medicaid/Medicare/other government insurance | 62 (24%) | 3605 (11%) | 8 (38%) | 1812 (19%) | ||
| Unknown | 8 (3%) | 613 (2%) | 0 (0%) | 206 (2%) | ||
| Income (per year) | 0.38 | 0.68 | ||||
| Less than $38 k | 40 (15%) | 3981 (12%) | 5 (24%) | 1507 (16%) | ||
| $38 k-62,999 | 115 (44%) | 15,408 (48%) | 10 (48%) | 4791 (49%) | ||
| $63 k or greater | 100 (39%) | 12,407 (39%) | 6 (29%) | 3256 (34%) | ||
| Unknown | 4 (2%) | 408 (1%) | 0 (0%) | 154 (2%) | ||
| Percent in ZIP code without a high school degree | 0.69 | 0.75 | ||||
| 21% or greater | 37 (14%) | 4450 (14%) | 5 (24%) | 1711 (18%) | ||
| 7–20.9% | 147 (57%) | 17,658 (55%) | 12 (57%) | 5355 (55%) | ||
| Less than 7% | 71 (27%) | 9716 (30%) | 4 (19%) | 2496 (26%) | ||
| Unknown | 4 (2%) | 380 (1%) | 0 (0%) | 146 (2%) | ||
| Residence | 0.42 | 0.51 | ||||
| Metropolitan | 221 (85%) | 26,877 (84%) | 16 (76%) | 7934 (82%) | ||
| Urban/rural | 38 (15%) | 5327 (17%) | 5 (24%) | 1774 (18%) | ||
| Charlson-Deyo comorbidity score | 0.016 | < 0.001 | ||||
| 0 | 237 (92%) | 30,544 (95%) | 15 (71%) | 9029 (93%) | ||
| 1 or more | 22 (9%) | 1660 (5%) | 6 (29%) | 679 (7%) | ||
| Stage | 0.21 | |||||
| Stage I | 259 (100%) | 32,204 (100%) | – | – | ||
| Stage II | – | – | 9 (43%) | 5469 (56%) | ||
| Stage III | – | – | 12 (57%) | 4239 (44%) | ||
| Treatment | < 0.001 | < 0.001 | ||||
| No orchiectomy | 0 (0%) | 30 (0.1%) | 2 (10%) | 634 (7%) | ||
| Orchiectomy alone | 250 (97%) | 16,519 (51%) | 10 (48%) | 1106 (11%) | ||
| Orchiectomy + adjuvant therapy | 9 (4%) | 15,626 (49%) | 9 (43%) | 7941 (82%) | ||
| Other/unknown | 0 (0%) | 29 (0.1%) | 0 (0%) | 27 (0.3%) | ||
| Last contact or death, months from diagnosis, median (IQR) | N = 229 | N = 28,855 | < 0.001 | N = 20 | N = 8612 | 0.002 |
| 41 (22, 62) | 53 (29, 80) | 19 (8, 55) | 47 (24, 75) | |||
| Time from diagnosis to death, median (IQR) | N = 13 | N = 747 | N = 14 | N = 866 | ||
| 23 (18, 43) | 31 (14, 58) | 0.78 | 11 (7, 21) | 13 (4, 28) | 0.96 | |
GCTs = Germ cell tumors, IQR = Interquartile range, SCSTs = Sex cord stromal tumors
Table 3.
Univariable and multivariable Cox proportional hazards regression analysis on the association between sociodemographic and clinical characteristics and mortality of the overall cohort
| Univariable HR (95% CI) | Multivariable1 HR (95% CI) – Overall | |
|---|---|---|
| Tumor type | ||
| GCTs | Ref. | Ref. |
| SCSTs | 2.96 (2.03–4.33)*** | 1.68 (1.13–2.49)* |
| Age (per 5-year increase) | 1.21 (1.19–1.23)*** | 1.18 (1.16–1.20)*** |
| Race/ethnicity | ||
| Non-Hispanic White | Ref. | Ref. |
| Non-Hispanic Black | 1.80 (1.41–2.29)*** | 1.13 (0.89–1.45) |
| Hispanic/other | 1.27 (1.13–1.43)*** | 1.14 (1.01–1.30)* |
| Insurance | ||
| Private insurance | Ref. | Ref. |
| Uninsured | 2.63 (2.29–3.01)*** | 2.31 (2.01–2.66)*** |
| Medicaid/Medicare/other government insurance | 4.33 (3.88–4.83)*** | 2.72 (2.42–3.05)*** |
| Income (per year) | ||
| < $38,000 | Ref. | Ref. |
| $38,000–$62,999 | 0.71 (0.62–0.81)*** | 0.94 (0.82–1.09) |
| > $63,000 | 0.44 (0.38–0.50)*** | 0.76 (0.63–0.92)** |
| Percent in ZIP code without a high school diploma | ||
| > 21% | Ref. | Ref. |
| 7–20.9% | 0.63 (0.56–0.71)*** | 0.83 (0.73–0.96)* |
| < 7% | 0.43 (0.37–0.49)*** | 0.74 (0.61–0.90)** |
| Residence | ||
| Metropolitan | Ref. | Ref. |
| Urban/rural | 1.49 (1.33–1.67)*** | 1.13 (1.00–1.29) |
| Charlson-Deyo comorbidity score | ||
| 0 | Ref. | Ref. |
| > 1 | 3.23 (2.82–3.70)*** | 2.06 (1.79–2.37)*** |
CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors
*p < 0.05
**p < 0.01
***p < 0.001
1The following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity score
Table 4.
Multivariable Cox proportional hazards regression analysis on the association between sociodemographic and clinical characteristics and mortality by stage
| Multivariable1 HR (95% CI) – Stage I | Multivariable1 HR (95% CI) – Stage II/III | |
|---|---|---|
| Tumor type | ||
| GCTs | Ref. | Ref. |
| SCSTs | 1.06 (0.60–1.86) | 3.28 (1.88–5.73)*** |
| Age (per 5-year increase) | 1.23 (1.20–1.26)*** | 1.13 (1.10–1.16)*** |
| Race/ethnicity | ||
| Non-Hispanic White | Ref. | Ref. |
| Non-Hispanic Black | 1.18 (0.80–1.72) | 1.13 (0.81–1.56) |
| Hispanic/other | 1.14 (0.95–1.38) | 1.12 (0.94–1.32) |
| Insurance | ||
| Private insurance | Ref. | Ref. |
| Uninsured | 2.58 (2.08–3.21)*** | 2.07 (1.72–2.50)*** |
| Medicaid/Medicare/other government insurance | 3.15 (2.64–3.75)*** | 2.31 (1.97–2.70)*** |
| Income (per year) | ||
| < $38,000 | Ref. | Ref. |
| $38,000–$62,999 | 0.92 (0.74–1.15) | 0.96 (0.79–1.16) |
| > $63,000 | 0.74 (0.56–0.98)* | 0.79 (0.61–1.02) |
| Percent in ZIP code without a high school diploma | ||
| > 21% | Ref. | Ref. |
| 7–20.9% | 0.87 (0.70–1.07) | 0.80 (0.67–0.97)* |
| < 7% | 0.80 (0.61–1.06) | 0.67 (0.52–0.88)** |
| Residence | ||
| Metropolitan | Ref. | Ref. |
| Urban/rural | 1.18 (0.98–1.42) | 1.09 (0.91–1.29) |
| Charlson-Deyo comorbidity score | ||
| 0 | Ref. | Ref. |
| > 1 | 2.03 (1.64–2.51)*** | 2.03 (1.68–2.45)*** |
CI = Confidence interval, GCTs = Germ cell tumors, HR = Hazard ratio, SCSTs = Sex cord stromal tumors
*p < 0.05
**p < 0.01
***p < 0.001
1The following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity score
Reference
- 1.Zuniga KB, et al. A comparison of stage-specific all-cause mortality between testicular sex cordstromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020;20:40. doi: 10.1186/s12894-020-00609-2. [DOI] [PMC free article] [PubMed] [Google Scholar]